Senti Biosciences, Inc. (NASDAQ:SNTI) Sees Large Increase in Short Interest

Senti Biosciences, Inc. (NASDAQ:SNTI) was the recipient of a significant increase in short interest in December. As of December 15th, there was short interest totaling 1,663,760 shares, an increase of 458.4% from the November 30th total of 297,970 shares. Currently, 6.5% of the shares of the stock are sold short. Based on an average daily trading volume, of 7,431,668 shares, the short-interest ratio is currently 0.2 days. Based on an average daily trading volume, of 7,431,668 shares, the short-interest ratio is currently 0.2 days. Currently, 6.5% of the shares of the stock are sold short.

Senti Biosciences Stock Down 7.8%

SNTI stock opened at $1.06 on Friday. Senti Biosciences has a 52-week low of $1.06 and a 52-week high of $5.10. The stock has a market cap of $27.87 million, a price-to-earnings ratio of -0.32 and a beta of 2.08. The business has a fifty day moving average of $1.79 and a two-hundred day moving average of $1.81.

Senti Biosciences (NASDAQ:SNTI) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.10). As a group, sell-side analysts anticipate that Senti Biosciences will post -14.54 EPS for the current year.

Wall Street Analysts Forecast Growth

SNTI has been the subject of a number of recent research reports. Wall Street Zen upgraded shares of Senti Biosciences to a “sell” rating in a report on Saturday, December 13th. Leerink Partnrs raised Senti Biosciences to a “strong-buy” rating in a report on Friday, November 21st. Leerink Partners began coverage on Senti Biosciences in a research report on Friday, November 21st. They set an “outperform” rating and a $6.00 price objective on the stock. HC Wainwright initiated coverage on Senti Biosciences in a research note on Tuesday, October 14th. They set a “buy” rating and a $12.00 price objective on the stock. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Senti Biosciences in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Senti Biosciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.00.

Hedge Funds Weigh In On Senti Biosciences

A number of hedge funds and other institutional investors have recently bought and sold shares of SNTI. Citadel Advisors LLC purchased a new stake in Senti Biosciences during the third quarter worth about $117,000. Geode Capital Management LLC grew its holdings in shares of Senti Biosciences by 395.6% in the second quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock valued at $311,000 after purchasing an additional 117,588 shares in the last quarter. Heights Capital Management Inc. purchased a new stake in Senti Biosciences during the 1st quarter worth approximately $2,520,000. Nantahala Capital Management LLC acquired a new stake in Senti Biosciences during the 1st quarter worth approximately $2,984,000. Finally, Armistice Capital LLC acquired a new stake in Senti Biosciences during the 2nd quarter worth approximately $1,883,000. 25.70% of the stock is currently owned by hedge funds and other institutional investors.

Senti Biosciences Company Profile

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.